West Pharmaceutical Services, Inc. (WST)

WST Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	493.7	492.7	593.4	585.9	661.8
Depreciation & Amortization	171.4	155.4	137.3	120.6	122.3
Stock-Based Compensation	23.8	18.7	23.3	23.7	37.5
Other Adjustments	-13.9	-16.3	42.9	8.8	-39.5
Change in Receivables	6.9	-58.8	4	-35.6	-123.5
Changes in Inventories	-62.8	42	-13.5	-49.8	-86.5
Changes in Accounts Payable	17.9	2.9	4.4	-2.8	16.8
Changes in Other Operating Activities	117.8	16.8	-15.3	73.2	-4.9
Operating Cash Flow	754.8	653.4	776.5	724	584
Operating Cash Flow Growth	15.52%	-15.85%	7.25%	23.97%	23.60%
Capital Expenditures	-285.9	-377	-362	-284.6	-253.4
Payments for Business Acquisitions	-	-	-	-	-2.2
Other Investing Activities	-	-1.7	-6.7	-3.6	2.5
Investing Cash Flow	-285.9	-378.7	-368.7	-288.2	-253.1
Long-Term Debt Issued	-	-	164.7	-	-
Long-Term Debt Repaid	-1.1	-192.3	-2.4	-44.3	-2.2
Net Long-Term Debt Issued (Repaid)	-1.1	-192.3	162.3	-44.3	-2.2
Issuance of Common Stock	18.2	32.7	51	28.2	37.1
Repurchase of Common Stock	-136.8	-566.6	-451.2	-222.2	-151.9
Net Common Stock Issued (Repurchased)	-118.6	-533.9	-400.2	-194	-114.8
Common Dividends Paid	-61.2	-59.1	-57	-54.1	-51.1
Other Financing Activities	-4.2	-2	-	-1.2	-
Financing Cash Flow	-185.1	-622.6	-459.6	-293.6	-168.1
Effect of Exchange Rate Changes on Cash and Cash Equivalents	22.9	-21.4	11.4	-10.5	-15.7
Net Cash Flow	306.7	-369.3	-40.4	131.7	147.2
Free Cash Flow	468.9	276.4	414.5	439.4	330.6
Free Cash Flow Growth	69.64%	-33.32%	-5.67%	32.91%	10.90%
FCF Margin	15.25%	9.55%	14.05%	15.22%	11.68%
Free Cash Flow Per Share	6.45	3.75	5.50	5.80	4.33
Levered Free Cash Flow	465.4	155.2	524.3	418.9	474
Unlevered Free Cash Flow	424.94	305.36	308.45	466.77	438.91

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q